Can you take Abrocitinib with Rilonacept?

Abrocitinib has a major potential interaction with Bladder Cancer.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Abrocitinib has a major potential interaction with Cardiovascular Conditions and Disorders.

Deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in patients receiving abrocitinib. Patients 50 years of age and older with at least one cardiovascular risk factor, had higher rates of overall thrombosis, DVT, and PE. Avoid abrocitinib in patients that may be at increased risk of thrombosis.

Abrocitinib has a major potential interaction with Cardiovascular Conditions and Disorders.

Major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and non-fatal stroke were observed in clinical studies with abrocitinib. Patients over 50 years old, current or past smokers, and patients with at least one cardiovascular risk factor were shown to have a higher risk. Consider the risks and benefits for each patient prior to initiating therapy with this drug, particularly in those that have cardiovascular risk factors including smoking.

Abrocitinib has a major potential interaction with Heart Disease.

Major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and non-fatal stroke were observed in clinical studies with abrocitinib. Patients over 50 years old, current or past smokers, and patients with at least one cardiovascular risk factor were shown to have a higher risk. Consider the risks and benefits for each patient prior to initiating therapy with this drug, particularly in those that have cardiovascular risk factors including smoking.

Rilonacept has a moderate potential interaction with High Cholesterol.

Patients treated with rilonacept experienced increases in their mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. The mean increases from baseline for total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were 19 mg/dL, 2 mg/dL, 10 mg/dL, and 57 mg/dL respectively after 6 weeks of open-label therapy. Physicians should monitor the lipid profiles of their patients especially those with hyperlipidemias, and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.

Abrocitinib has a major potential interaction with History, Skin Cancer.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Abrocitinib has a major potential interaction with Infection.

Serious infections leading to hospitalization or death, including tuberculosis (TB) and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving JAK inhibitors such as abrocitinib. Abrocitinib should be avoided in patients with active serious infections, including localized infections. Treatment with abrocitinib is not recommended in patients with active TB, or in patients with active hepatitis B or C, as viral reactivation has been reported. Consider the risks and benefits of treatment prior to initiating therapy in patients with chronic or recurrent infections, exposed to tuberculosis, with a history of opportunistic infections, or underlying conditions that predispose to infection. Caution and close monitoring for signs and symptoms of infection is recommended during treatment.

Rilonacept has a moderate potential interaction with Infection.

Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with other medication as rilonacept, that work through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking rilonacept compared with placebo. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with an active or chronic infection. Additionally, latent tuberculosis can be reactivated and should be treated before initiating therapy with rilonacept.

Abrocitinib has a moderate potential interaction with Liver Disease.

Abrocitinib is not recommended for use in patients with severe hepatic impairment.

Rilonacept has a moderate potential interaction with Liver Disease.

No formal studies have been conducted to examine the pharmacokinetics of rilonacept administered subcutaneously in patients with hepatic impairment. Caution is advised if used on these patients.

Abrocitinib has a major potential interaction with Lung Cancer.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Abrocitinib has a major potential interaction with Lymphoma.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Abrocitinib has a major potential interaction with Neoplasia, Estrogen Dependent.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Abrocitinib has a moderate potential interaction with Renal Dysfunction.

Abrocitinib is not recommended for use in patients with severe renal impairment (eGFR less than 30 mL/min) and end-stage renal disease (eGFR less than 15 mL/min).

Rilonacept has a moderate potential interaction with Renal Dysfunction.

No formal studies have been conducted to examine the pharmacokinetics of rilonacept administered subcutaneously in patients with renal impairment. Caution is advised if used on these patients.

Abrocitinib has a major potential interaction with Smoking.

Major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and non-fatal stroke were observed in clinical studies with abrocitinib. Patients over 50 years old, current or past smokers, and patients with at least one cardiovascular risk factor were shown to have a higher risk. Consider the risks and benefits for each patient prior to initiating therapy with this drug, particularly in those that have cardiovascular risk factors including smoking.

Abrocitinib has a major potential interaction with Smoking.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Rilonacept has a moderate potential interaction with Tuberculosis, Latent.

Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with other medication as rilonacept, that work through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking rilonacept compared with placebo. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with an active or chronic infection. Additionally, latent tuberculosis can be reactivated and should be treated before initiating therapy with rilonacept.

Rilonacept has a major potential interaction with Vaccination.

Live vaccines should not be given concurrently with rilonacept. Rilonacept may interfere with normal immune response to new antigens; therefore, vaccinations may not be effective in patients receiving rilonacept. No data are available on the effectiveness of vaccination with inactivated (killed) antigens in patients receiving rilonacept. Because IL-1 blockade may interfere with immune response to infections, it is recommended that prior to initiation of therapy with rilonacept adult and pediatric patients receive all recommended vaccinations, as appropriate, including pneumococcal vaccine and inactivated influenza vaccine.